Research Our research is focused at identification and implementation of new cancer biomarkers, identification and characterization of novel targets for future cancer treatment and identification of molecular mechanisms underlying the behaviour of cancer stem cells as well as their normal counterparts. We currently house 6 research groups working on projects relevant for cancer. Behrendt Group Behrendt Group is focused on cellular invasion and matrix degradation through extracellular and endocytic mechanisms, with particular emphasis to collagen matrices. 14. March 2019 / 13:26 Engelholm Group The main focus area in this research group is collagen turnover in pathological and physiological conditions in mammals. We try to elucidate some of the mechanisms behind dysregulated collagen homeostasis in cancer and several other pathological diseases with either collagen accumulation (fibrosis) or excess collagen degradation (e.g. osteoporosis). 13. March 2019 / 15:05 Ploug Group Our research is focused on structural and functional aspects of proteins involved in cellular invasion and matrix degradation. The ultimate goal of these studies is to elucidate the function of these proteins in vitro and in vivo and to facilitate the translation of these findings into a clinical setting, particularly within the field of oncology. 14. March 2019 / 13:51 Porse Group Cancer is a devasting disease targeting millions of people world-wide. In order to develop normal targeted therapies to combat cancer we need detailed understanding of the molecular mechanisms governing both the initiation and maintenance of cancer. Furthermore, to forward novel candidate targets for future drug development we also need to understand their function in the corresponding normal tissues. 20. March 2019 / 14:32 Theilgaard-Mönch Group The major focus of the Theilgaard-Mönch group is to compare cancer cells to their closest normal cellular counterpart using a variety of omics technologies in order to improve prognostication as well as identify novel targets for treatment of patients with acute myeloid leukaemia (AML). 19. January 2018 / 13:11 Weischenfeldt Group Cancer is a genetic disease and is caused by accumulation of genomic alterations that improve the fitness of the cell. We utilize cancer genomics approaches to characterize the mechanisms, functional consequences and prognostic relevance of genomic alterations in cancer. 14. March 2019 / 14:42 (Webid:472a668a-a1d9-4445-81be-947ba4b89584) ContentTypeId:0x010100C568DB52D9D0A14D9B2FDCC96666E9F2007948130EC3DB064584E219954237AF39009452EC1D623246A98E3D4F4B956DBBB600B52690698F9B4317A25D71E6FF9098B4* ( PublishingDate>1970-01-01) TaggedTags:* -
Behrendt Group Behrendt Group is focused on cellular invasion and matrix degradation through extracellular and endocytic mechanisms, with particular emphasis to collagen matrices. 14. March 2019 / 13:26
Engelholm Group The main focus area in this research group is collagen turnover in pathological and physiological conditions in mammals. We try to elucidate some of the mechanisms behind dysregulated collagen homeostasis in cancer and several other pathological diseases with either collagen accumulation (fibrosis) or excess collagen degradation (e.g. osteoporosis). 13. March 2019 / 15:05
Ploug Group Our research is focused on structural and functional aspects of proteins involved in cellular invasion and matrix degradation. The ultimate goal of these studies is to elucidate the function of these proteins in vitro and in vivo and to facilitate the translation of these findings into a clinical setting, particularly within the field of oncology. 14. March 2019 / 13:51
Porse Group Cancer is a devasting disease targeting millions of people world-wide. In order to develop normal targeted therapies to combat cancer we need detailed understanding of the molecular mechanisms governing both the initiation and maintenance of cancer. Furthermore, to forward novel candidate targets for future drug development we also need to understand their function in the corresponding normal tissues. 20. March 2019 / 14:32
Theilgaard-Mönch Group The major focus of the Theilgaard-Mönch group is to compare cancer cells to their closest normal cellular counterpart using a variety of omics technologies in order to improve prognostication as well as identify novel targets for treatment of patients with acute myeloid leukaemia (AML). 19. January 2018 / 13:11
Weischenfeldt Group Cancer is a genetic disease and is caused by accumulation of genomic alterations that improve the fitness of the cell. We utilize cancer genomics approaches to characterize the mechanisms, functional consequences and prognostic relevance of genomic alterations in cancer. 14. March 2019 / 14:42